PM
ITCI

Parametrica Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Parametrica Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,072
Closed -$231K – 169
2022
Q2 		$231K Buy
+4,072
New +$231K 0.25% 110
2020
Q3 		– Sell
-11,296
Closed -$290K – 162
2020
Q2 		$290K Buy
+11,296
New +$229K 0.32% 80
2015
Q4 		– Sell
-5,400
Closed -$216K – 95
2015
Q3 		$216K Buy
+5,400
New +$176K 1.36% 40

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Parametrica Management's ITCI Position: Q3 2022 in Review

Parametrica Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2022, closing a stake of 4,072 shares — an estimated $231K sold.

Parametrica Management first reported a position in ITCI in Q3 2015 and held it in 3 quarters. The position peaked at $290K in Q2 2020. 274 funds tracked by Wall St. Rank hold ITCI as of Q3 2022.

  • Parametrica Management reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2022 after selling out during the quarter.
  • Parametrica Management sold 4,072 Intra-Cellular Therapies Inc. shares in Q3 2022, an estimated $231K.
  • Parametrica Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2015 and held it in 3 quarters.
  • Parametrica Management's Intra-Cellular Therapies Inc. position peaked at $290K in Q2 2020.
  • 274 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2022.

Based on Parametrica Management's 13F filing for Q3 2022, filed 3 Nov 2022.